Leerink Partnrs Weighs in on AstraZeneca Q2 Earnings

AstraZeneca PLC (NASDAQ:AZN) – Leerink Partnrs issued their Q2 2025 EPS estimates for shares of AstraZeneca in a report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens expects that the company will post earnings of $1.09 per share for the quarter. The consensus estimate for AstraZeneca’s current full-year earnings is $4.13 per share. Leerink Partnrs also issued estimates for AstraZeneca’s Q3 2025 earnings at $1.11 EPS.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings data on Thursday, February 6th. The company reported $1.05 earnings per share for the quarter, missing the consensus estimate of $1.10 by ($0.05). AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%.

A number of other equities analysts also recently weighed in on the stock. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $89.75.

AstraZeneca Stock Down 0.5 %

Shares of AstraZeneca stock opened at $71.99 on Friday. AstraZeneca has a 1 year low of $60.47 and a 1 year high of $87.68. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. The company has a 50-day moving average of $67.38 and a 200 day moving average of $73.69. The firm has a market cap of $223.25 billion, a price-to-earnings ratio of 34.45, a PEG ratio of 1.18 and a beta of 0.46.

AstraZeneca Increases Dividend

The firm also recently announced a semi-annual dividend, which will be paid on Monday, March 24th. Shareholders of record on Friday, February 21st will be issued a $1.03 dividend. This is a positive change from AstraZeneca’s previous semi-annual dividend of $0.49. The ex-dividend date of this dividend is Friday, February 21st. This represents a dividend yield of 2%. AstraZeneca’s dividend payout ratio (DPR) is presently 43.36%.

Institutional Trading of AstraZeneca

Institutional investors have recently made changes to their positions in the stock. Martin Investment Management LLC grew its position in AstraZeneca by 2.8% during the third quarter. Martin Investment Management LLC now owns 284,204 shares of the company’s stock valued at $22,571,000 after buying an additional 7,615 shares during the period. Nordea Investment Management AB purchased a new position in shares of AstraZeneca during the 4th quarter worth $754,000. Diversify Wealth Management LLC increased its stake in shares of AstraZeneca by 3.6% in the 4th quarter. Diversify Wealth Management LLC now owns 4,402 shares of the company’s stock worth $295,000 after purchasing an additional 153 shares in the last quarter. Ameritas Advisory Services LLC lifted its position in AstraZeneca by 25.9% during the fourth quarter. Ameritas Advisory Services LLC now owns 9,487 shares of the company’s stock valued at $622,000 after purchasing an additional 1,949 shares in the last quarter. Finally, Integrated Advisors Network LLC grew its holdings in AstraZeneca by 46.6% during the third quarter. Integrated Advisors Network LLC now owns 43,610 shares of the company’s stock valued at $3,398,000 after purchasing an additional 13,860 shares during the period. Hedge funds and other institutional investors own 20.35% of the company’s stock.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.